|
|
|
|
| LEADER |
04174nmm a2200349 u 4500 |
| 001 |
EB001455346 |
| 003 |
EBX01000000000000000916216 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
170608 ||| eng |
| 020 |
|
|
|a 9789400776753
|
| 100 |
1 |
|
|a Patel, Vinood B.
|e [editor]
|
| 245 |
0 |
0 |
|a Biomarkers in Liver Disease
|h Elektronische Ressource
|c edited by Vinood B. Patel, Victor R. Preedy
|
| 250 |
|
|
|a 1st ed. 2017
|
| 260 |
|
|
|a Dordrecht
|b Springer Netherlands
|c 2017, 2017
|
| 300 |
|
|
|a 162 illus., 110 illus. in color. eReference
|b online resource
|
| 505 |
0 |
|
|a PNPLA3 polymorphism and Nonalcoholic Fatty Liver Disease -- Hepascore and it's application to liver disease -- Model for End-Stage Liver Disease (MELD) Score as a Biomarker -- Biomarkers in focus: Alanine Aminotransferase -- PTX3 as a biomarker of liver disease
|
| 505 |
0 |
|
|a Squamous Cell Carcinoma Antigen- Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinicalapplications -- microRNA-155 and microRNA-196b in hepatitis C virus infection -- Immunological biomarkers in liver transplantation -- Phosphatidylethanol and alcohol use in liver disease patients -- Interaction of sialyltransferases, sialidases and sialic acids in liver diseases and applications to biomarker discovery -- Biomarkers to monitor graft function following liver transplantation -- YKL-40 as a biomarker of liver diseases -- Peripheral venous, portal venous, hepatic venous, arterial and intrahepatic cytokine levels as biomarkers and functional correlations -- Histological Biomarkers of Non-Alcoholic Fatty Liver Disease -- Vascular cell adhesion molecule-1 (vcam-1) expression in liver disease -- Bilirubin as a biomarker in liver disease -- Hydroxyproline as a biomarker in liver disease -- Genetic biomarkers of paracetamol-induced acute liver failure --
|
| 505 |
0 |
|
|a Liver biomarkers and their applications to nutritional interventions in animal studies -- AST-to-platelet ratio index (APRI) as marker in liver disease.-Inflammatory biomarkers in ascites -- Biomarkers for hepatocellular carcinoma in East Asia -- Liver disease and acylcarnitines as mechanistic biomarkers.-Type VI Collagen: Biological Functions and its Neo-epitope as Hepatic Fibrosis Biomarker -- Fibrinogen α-chain as a serum marker of liver disease -- Monocyte chemotactic protein-1 (cytokine, receptors,and gene polymorphisms) in hepatitis -- Biomarkers for Recurrence of Hepatocellular Carcinoma.-Graft-derived cell-free DNA as a biomarker in liver transplantation -- Serum sialic acid as a biomarker in liver disease -- CD133 and EpCAM as Biomarkers in Liver Diseases -- Traditional markers in liver disease -- Biomarkers of extracellular matrix remodeling in liver diseases --
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Cancer Biology
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Preedy, Victor R.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Biomarkers in Disease: Methods, Discoveries and Applications
|
| 028 |
5 |
0 |
|a 10.1007/978-94-007-7675-3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-94-007-7675-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616,994
|
| 082 |
0 |
|
|a 571,978
|
| 520 |
|
|
|a There are numerous types of liver disease that may be due to toxic agents (such as alcohol or drugs), infectious agents including viruses, congenital conditions and even poor dietary patterns. It has been suggested that there are over 100 different types. As the consequences of liver failure can be devastating it is important that appropriate diagnosis and monitoring is carried out. Much of this characterisation entails the use of biological indicators, i.e biomarkers. Biomarkers in Liver Disease embraces a holistic approach by combining detailed information on different conditions that affect the liver and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge, trends and innovations. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry
|